Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04900363

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC

Sponsor: Akeso

Interventions AK112

Updated 7 times since 2021 Last updated: Feb 27, 2026 Started: May 21, 2021 Primary completion: Jun 28, 2024 Completion: Dec 9, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Akeso and has accumulated 7 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Apr 2025 — Mar 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Unknown → Active Not Recruiting
Nov 2024 — Apr 2025 [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 2 earlier versions

Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China